A new drug delivery strategy able to block pain within the nerve cells has been developed by researchers from Monash University. The creation could be a major development of an immediate and long lasting treatment for pain.
More than 100 million Americans suffer from chronic pain and this figure is expected to grow, driven by the increased life expectancy, increasing incidence of diabetes and cancer, combined with better survival rates, often leaving patients with severe and poorly treated pain. The global market for nerve pain treatments is over US$600 billion and yet current pain therapies are not completely effective and often suffer from unwanted side effects.
The study reveals how a target protein, long known to be associated with both chronic and acute pain, works within the nerve cell. This protein is the NK1 receptor, the receptor of the neuropeptide substance P, which mediates pain transmission.
Because of its association with pain and other diseases of the nervous system, many drug development attempts have focused on inhibiting this receptor, but the efficacy of these treatments has been very limited. This new work shows that such ineffectiveness could be in part because the treatments targeted the protein on the surface of the nerve cell.
NK-1 Receptor
Dr Michelle Halls and Dr Meritxell Canals from the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre for Excellence in Bio-Nano Science (CBNS) at Monash University, have worked with Professor Nigel Bunnett, previously at Monash and now at Columbia University in the US, and Professor Chris Porter from MIPS and CBNS.
Together they have found that the NK-1 receptor controls pain once it is inside the cell – so drugs that merely block it when it is on the surface of the cell have little efficacy. Instead, this new research shows that, in animal models, if the NK-1 receptor is blocked once it enters the nerve cell, it is possible to suppress pain more effectively.
Dr Halls said that the new strategy of targeting receptors inside the cell represents a new frontier in drug delivery and a novel therapeutic strategy for dealing with pain.
Working with a multidisciplinary team of cell biologists, pharmacologists, physiologists and drug delivery experts, the researchers developed drugs that specifically target NK-1 receptors within the nerve cell. Animal studies showed that using the drugs – which have an engineered lipid attachment that targets the drug to the NK-1 receptor inside the cell, could block pain for extended periods in several animal models.
Dane D. Jensen, TinaMarie Lieu, Michelle L. Halls, Nicholas A. Veldhuis, Wendy L. Imlach, Quynh N. Mai, Daniel P. Poole, Tim Quach, Luigi Aurelio, Joshua Conner, Carmen Klein Herenbrink, Nicholas Barlow, Jamie S. Simpson, Martin J. Scanlon, Bimbil Graham, Adam McCluskey, Phillip J. Robinson, Virginie Escriou, Romina Nassini, Serena Materazzi, Pierangelo Geppetti, Gareth A. Hicks, Macdonald J. Christie, Christopher J. H. Porter, Meritxell Canals, Nigel W. Bunnett
Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief
Science Translational Medicine 31 May 2017: Vol. 9, Issue 392, eaal3447 DOI: 10.1126/scitranslmed.aal3447
Related Posts:
- Inhibitory Neurons: Model Sheds Light On Computational Role
- Imaging Metal-impregnated Neurons With Spectral Confocal Microscopy
- ALS-linked Protein Clusters May Actually Protect Neurons
Last Updated on December 14, 2022